Neuronal Responses to Social Feedback in Major Depressive Disorder



Status:Completed
Conditions:Depression, Depression, Major Depression Disorder (MDD)
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 55
Updated:7/11/2015
Start Date:October 2013
End Date:October 2014
Contact:Benjamin J Sanford, B.S.
Email:bensan@umich.edu
Phone:(734) 615-2698

Use our guide to learn which trials are right for you!

The overall goal of the proposed project is to investigate the neuronal pathways regulating
the effects of social acceptance and rejection in healthy controls and patients with Major
Depressive Disorder (MDD). Social acceptance and rejection are defined as the explicit
declaration that an individual is liked or not liked. Social acceptance can boost one's
self-esteem and mood, whereas rejection can lower them. The neurological relationship
between social acceptance/rejection and depressive symptoms is not known. Using functional
magnetic resonance imaging (fMRI), it is hypothesized that social feedback will activate a
specific interconnected neuronal pathway involved in social separation and reward.
Executive functioning and response to monetary reward will also be assessed during fMRI
using two additional tasks (monetary incentive delay, parametric go no-go) to determine how
these cognitive brain functions regulate responses to social feedback.


Inclusion Criteria:

- Men and women between 18 and 55 years of age

- No use of psychotropic medications in the past 4 weeks

- No regular tobacco use, and who are able to make decisions for his or her self
-Patients who meet criteria for (DSM-IV) Major Depressive Disorder or Depressive
Disorder Not Otherwise Specified, with Hamilton Depression Rating Scale scores ≥ 10,
and may be on monotherapy (treatment for MDD with a single SSRI)

- MDD patients will be matched with healthy controls for age and education.

Exclusion Criteria:

- No serious medical illnesses or major physiological disturbance during the past three
months (e.g., serious infections or pregnancy) or anemia Any other Axis I psychiatric
disorder

- Pharmacological exclusion criteria include the use of psychoactive substances during
past 3 months (e.g., barbiturates, anticonvulsants glutethimide, alpha-methyl dopa,
corticosteroids [oral or topical creams], opiates or codeine, cyproheptadine, opioid
analgesics, antipsychotic drugs)

- History of DSM-IV alcohol or drug dependence within the past 5 years

- Drug or alcohol abuse in the past 2 years or a CAGE Alcohol Screening Inventory score
of >3

- Regular alcohol use during the past 6 months equal to or greater than 16 cans of beer
per week or equivalent; use of street drugs during the past 2 years

- Regular tobacco use, since nicotine stimulates cortisol secretion even in smokers;

- Major chronobiological disruption or phase shift during the preceding month (e.g.,
total sleep deprivation, reversal of sleep-wake cycles or trans-meridian travel)

- Childbirth or miscarriage within 6 months

- Breastfeeding within 6 months of recruitment

- Progestin-only birth controls (e.g., Cerazette, Ovrette)

- No contraindications to MRI scan including neurostimulators, metal in the body,
weight over 250 pounds, and girth size incompatible for MRI scanner bore

- No non-right-handed subjects

- For healthy controls, subjects will have no history of psychiatric problems in
themselves or any first-degree relatives
We found this trial at
1
site
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials